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It is generally accepted that primary lung cancer represents one
of the most aggressive solid tumours and its prognosis is still
poor despite intensive application of improved therapy. It is not
rare for metastatic lesions to already be discovered at the initial
diagnosis. Approximately 80% of primary lung cancer is
histopathologically diagnosed as non-small-cell lung carcinoma
(NSCLC) (el-Torky et al, 1990), and generally surgical treat-
ments are applied to relatively early stage of NSCLC cases.
However, distant metastasis occurs in most of these patients
within a few years and local recurrence also appears in a few
cases. The 5-year survival rate of surgically treated cases with
early-stage NSCLC is only 50–60% (Ginsberg and Rubinstein,
1995). This incident suggests that some molecular mechanisms
of lung cancer progression might markedly influence the
progression of NSCLC. Recently, some evidence that several
kinds of molecules reflect distant metastasis and local invasion
of cancer cells has been presented (Gasparini, 1996; Stetler-
Stevenson et al, 1996). 
It has been clarified that angiogenesis is an essential process
required for the growth and metastasis of solid tumours
(Folkman, 1985). In this context, several growth factors with
angiogenic activity in lung cancer have been reported, such as
VEGF, PD-ECGF, FGF (Gasparini, 1996). Some investigations
showed the vascularization and progress of metastases associ-
ated with the expression of VEGF (Volm et al, 1999; Yano et al,
2000). The expression levels of VEGF in stage I NSCLC were
significantly different between cases with recurrence (46.5%)
and without recurrence (11.5%) (Ohta et al, 1999). Furthermore,
the co-expression of VEGF, PD-ECGE and bFGF were signifi-
cantly associated with lymph node involvement and prognostic
information (Volm et al, 1999; O’Byrne et al, 2000). 
On the other hand, it was clarified that the degradation of the
extracellular matrix and penetration of basement membranes
played an important role in tumour invasion and metastasis
(Kleiner and Steler-Stevenson, 1999). Several reports showed
that the levels of the matrix metalloproteinase (MMP) family
are associated with the lysis of basement membranes and with
tumour invasion (Stetler-Stevenson et al, 1996). The expression
of MMP-2 or MMP-9 confers a worse prognosis in early stage
adenocarcinoma of the lung (Kodate et al, 1997; Passlick et al,
2000). However, a few investigators reported that there was no
significant correlation between expression of MMP-9 and
the prognosis in patients with NSCLC (Fujise et al, 2000).
Though the regulatory pathways for these kinds of molecules
seem to be complex, recent research showed that a significant
proportion of NSCLC tumours co-express MMP-9 and EGFR,
and that their co-expression conferred a poor prognosis (Cox
et al, 2000). 
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Summary We attempted to investigate immunohistochemical expression of vascular endothelial growth factor (VEGF), basic fibroblast
growth factor (bFGF), platelet-derived growth factor (PD-ECGF), c-erbB-2, matrix metalloproteinase-2 (MMP-2), and MMP-9 using surgical
specimens of 119 non-small-cell lung carcinoma (NSCLC) cases and to evaluate the relationship between the expression levels of each
molecule and clinicopathological factors or prognosis. VEGF expression levels were significantly associated with the local invasion (P =
0.0001), lymph node involvement (pN-factor) (P = 0.0019), pathological stage (p-stage) (P = 0.0027) and lymphatic permeation (P = 0.0389).
PD-ECGF expression levels were associated with pN-factor (P = 0.0347). MMP-2 expression levels were associated with pN-factor (P =
0.004) and lymphatic permeation (P = 0.0056). Also, MMP-9 expression levels showed a significant correlation to local invasion (P = 0.0012),
pN-factor (P = 0.0093) and p-stage (P = 0.0142). Multivariate analysis showed VEGF to be the most related to local invasion (P = 0.0084),
and MMP-2 was the only factor with significant independent impact on lymphatic permeation (P = 0.0228). Furthermore, log-rank analysis
showed significant association with poor survival by VEGF, bFGF, MMP-2 and MMP-9. Especially, combined overexpression of VEGF and
MMP-2 revealed poor prognosis, our study might provide a basis for the better evaluation of biological characteristics and a new therapeutic
strategy based on chemotherapy. © 2001 Cancer Research Campaign http://www.bjcancer.com
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In our study, we attempted to clarify the relationship between
the expression of VEGF, bFGF, PD-ECGF, MMP-2, MMP-9 and
c-erbB-2 in NSCLC and clinicopathological characteristics.
Furthermore, the relationship between each molecule and survival
was evaluated. 
MATERIALS AND METHODS 
Patients and tumour specimens 
Surgical materials were obtained from 119 patients with NSCLC
lesions resected between May 1994 and December 1995 at the
Department of Surgery, Tokyo Medical University Hospital. The
age of patients ranged from 38 to 81 years (average age 63.6
years). There were 87 men and 32 women and cases were patho-
logically diagnosed as adenocarcinoma in 80 cases, squamous cell
carcinomas in 37 cases, adenosquamous carcinoma in one case
and large-cell carcinoma in one case. The pathological stage was
evaluated according to the TNM classification (Mountain, 1997).
The pathological stages of these cases were categorized as: stage
IA 28 cases; stage IB 19 cases; stage IIA 6 cases; stage IIB 20
cases; stage IIIA 35 cases; stage IIIB 11 cases. 
The surgical materials were fixed by acetone and subsequently
embedded in paraffin (Sato et al, 1986). The sections were cut at a
thickness of 4 µ m, collected on silane-coated slides and stored at
4˚C until use. 
Immunohistochemistry 
The immunohistochemical staining was performed with the
avidin–biotin peroxidase complex (ABC) method (Hsu et al,
1981) by using a Vectastain ABC Kit. The sections were dewaxed
in xylene and rehydrated with graded alcohol. The endogenous
peroxidase activity was inhibited by incubation with 0.5%
hydrogen peroxidase in methanol for 30 min. The sections were
then washed in phosphate-buffered saline (PBS), and incubated in
2% normal swine serum in PBS to block nonspecific binding. The
specimens were reacted with each primary antibody overnight at
4˚C. After washing 3 times in PBS, either biotinylated-anti-rabbit,
anti-mouse or anti-goat immunoglobulins were used as the second
antibody (diluted 1:200). After 30 min of incubation with the
second antibody, the sections were washed again with PBS.
Avidin–biotin peroxidase complex, diluted 1:200 using a vectas-
tain Kit (Vector Laboratories, Inc Burlingame, CA, USA) was
applied for 30 min. After washing, the specimens were reacted
with 3,3′ -diaminobenzidine tetrahydrochloride (DAB), supple-
mented with 0.02% hydrogen peroxide in Tris-buffer to visualize
the positive area, and then the sections were counterstained with
haematoxylin, washed in tap water, dehydrated in alcohol, cleared
in xylene and mounted. Negative control slides were prepared
using PBS instead of the specific primary antibody. 
As the primary antibody, we used anti-VEGF (A-20) rabbit
polyclonal antibody (1:400, Santa Cruz Biotechnology, Inc. CA,
USA), Anti-bFGF mouse monoclonal antibody (1:200, Wako Pure
Chemical Industries, Osaka, Japan), anti-MMP-2 (C-20) goat
polyclonal antibody (1:200, Santa Cruz Biotechnology, Inc. 
CA, USA), and anti-MMP-9 (C-19) goat polyclonal antibody
(1:200, Santa Cruz Biotechnology, Inc, CA, USA), anti-c-erbB-2
rabbit polyclonal antibody (Nichirei, Tokyo, Japan), and anti-
PD-ECGF mouse monoclonal antibody 1C6-203 (1:200, a gift
kindly provided by Dr Tanaka, Nippon Roche Research Center,
Kamakura, Japan) (Kono et al, 2001). 
Evaluation of immunohistochemical results 
Morphologically histopathological features and immunohisto-
chemical staining were evaluated, independently. More than 300
cancer cells were counted in several fields, which were selected at
random. Cases with brown cytoplasm were considered positive.
The positive cancer cells were counted and positive rate was
calculated. Furthermore, we evaluated the expression levels of
each molecule as positive (+: mean – standard deviation or more in
positive cells) and negative (–: less than mean – standard deviation
in positive cells). We evaluated survival probability according to
this classification. 
Statistical analysis 
Data were expressed as means ± standard deviation. Statistical
analysis was performed using the StatView software system
(StatView 5.0.1, SAS Institute Inc). Student’s t-test was used to
analyse the association between categorical clinicopathological
variables. For multivariate analysis, logistic regression and step-
wise regression analysis were used. Survival curves were calcu-
lated from the day of operation by the Kaplan–Meier method and
the significance of the difference in the survival rates between the
patient groups was calculated by the log-rank test. A P value 
of less than 0.05 was taken to indicate statistically significant
difference. 
RESULTS 
Immunohistochemical analysis of VEGF, bFGF, 
PD-ECGF, c-erbB-2, MMP-2, MMP-9 based on
clinicopathological data 
The clinicopathological factors of the 119 patients are summarized
in Table 1. Each molecule expressed mainly in the cytoplasm 
Table 1 The clinicopathological factors of the 119 patients with NSCLC 
Characteristics No. (%) 
Total 119 
Sex Male 87 (73.1) 
Female 32 (26.9) 
Age Mean (years) 63.6 
Adenocarcinoma 80 (72.3) 
Histology Squamous cell carcinoma 37 (31.9) 
Adenosquamous carcinoma 1 (0.84) 
Large cell carcinoma 1 (0.84) 
Tumor size T1 43 (36.1) 
T2 57 (47.9) 
T3 12 (10.1) 
T4 7 (5.9)
Lymph node metastasis – 56 (47.1) 
+ 63 (52.9) 
Lymphatic permeation – 57 (47.9) 
+ 53 (44.5) 
Vascular involvement – 58 (48.7) 
+ 55 (46.2) 
Pathological stage I 47 (39.5) 
II 26 (21.8) 
III 46 (38.7) 1708 Y Shou et al
British Journal of Cancer (2001) 85(11), 1706–1712 © 2001 Cancer Research Campaign
of cancer cells. The positive rates of VEGF, bFGF, PD-ECGF,
MMP-2, MMP-9 and c-erbB-2 in 119 patients were 76 (63.9%),
92 (77.3%), 68 (57.1%), 87 (73.1%), 78 (65.5%) and 93
(78.2%), respectively. The relationships between expression
of these molecules and TNM classification, vascular involve-
ment and lymphatic permeation are shown in Table 2. We
divided all patients into one group consisting of pathological 
T1 (pT1) and pT2, and the other group consisting of pT3
and pT4. There were statistically significant differences in
VEGF (P = 0.0001) and MMP-9 (P = 0.001) between the 2
groups (Table 2). 2 pathological N factor (pN-factor) groups
were established according to cases with lymph node involve-
ment (N+) and case without lymph node involvement (N–):
there were statistically significantly differences in VEGF
(P = 0.0019), PD-ECGF (P = 0.034), MMP2 (P = 0.004) and
MMP9 (P = 0.009) between the 2 groups. Depending on
whether the case is pathological stage I (p-stage I) or not
(p stage II, III), statistically significant differences could be
observed in VEGF (P = 0.0027) and MMP9 (P = 0.0142)
between the 2 p stage groups. Comparing cases according to the
presence or absence of either vascular involvement or lymphatic
permeation, statistically significant differences were seen in
both VEGF (P = 0.0369) and MMP-2 (P = 0.0056) between
cases with and cases without lymphatic permeation. However,
we did not observe a statistically significant difference in any
molecule with regard to vascular involvement. 
To investigate which is the most important variable associ-
ated with the clinicopathological factors, stepwise regression
and logistic regression analysis were performed. As a result of
multivariate analysis, we found VEGF was the most closely
associated with local invasion (pT1 and pT2 vs. pT3 and pT4:
P = 0.0084), and MMP-2 was the only characteristic to have a
significant independent impact on lymphatic permeation
(P = 0.0228). 
Relationship between expression levels of each
molecule and prognosis 
For survival analyses, survival data were available for 111
patients. Patients dying within 60 days of surgery were 
excluded to avoid bias from perioperative death. The deaths of
all other patients were cancer-related death. The 3-year and
5-year survival rates for the 111 patients were 59.4% and 
47.4%, respectively, with a median survival of 36.0 months.
Univariate analysis of survival probability showed that the
expression of VEGF (P = 0.0083), bFGF (P = 0.0173), MMP-2
(P = 0.0149), MMP-9 (P = 0.0126) were significantly associated
with a worse prognosis (Figure 1A–D). The 5-year survival 
rates of cases with VEGF, bFGF, MMP-2 and MMP-9 positive 
were 37.5%, 41.2%, 40.9%, 38.4%, respectively, whereas they
were 64.4%, 73.6%, 69.0% and 68.3% when VEGF, bFGF,
MMP-2 and MMP-9 were negative. No association was
observed between expression of PD-ECGF (P = 0.8198) or
c-erbB-2 (P = 0.3004) and survival probability (Figure 1E, F). 
Cases with co-expression of VEGF and MMP-2 were found in
65 out of the 111 (58.6%) and were associated with a poor
Table 2 Relationships between expression of VEGF, bFGF, PD-ECGF, c-erbB-2, MMP-2, MMP-9 and clinicopathological factors in 119 patients with NSCLC 
No. of cases Expression (mean ± SD) (%) 
VEGF bFGF PD-ECGF MMP-2 MMP-9 c-erbB-2 
pT-factor 
PT1, pT2 43 25.58 ± 27.63 39.30 ± 24.04 26.28 ± 26.64 36.74 ± 26.34 24.19 ± 19.18 49.07 ± 30.22 
PT3, pT4 76 45.40 ± 25.16 48.16 ± 24.64 35.92 ± 26.34 43.82 ± 24.38 37.24 ± 21.33 50.40 ± 28.21 
P value 0.0001 0.0599 0.0585 0.1426 0.0012 0.8109 
pN-factor 
PN (–) 56 30.00 ± 26.22 40.36 ± 27.43 26.96 ± 25.36 34.29 ± 25.36 27.14 ± 20.25 48.75 ± 31.51 
PN (+) 63 45.56 ± 27.05 49.05 ± 21.38 37.30 ± 27.19 47.46 ± 23.62 37.30 ± 21.49 50.95 ± 26.44 
P value 0.0019 0.0550 0.0347 0.0040 0.0093 0.6793 
p stage 
I 47 28.94 ± 25.73 39.57 ± 26.94 28.30 ± 25.73 35.75 ± 26.19 25.60 ± 20.88 50.43 ± 31.55 
II, III 72 44.31 ± 27.36 48.47 ± 22.62 35.14 ± 27.22 44.86 ± 24.09 36.39 ± 21.05 49.58 ± 27.14 
P value 0.0027 0.0543 0.1736 0.0536 0.0142 0.8770 
Vascular 
involvementa
(–) 58 35.35 ± 28.73 43.79 ± 24.63 31.38 ± 25.44 37.93 ± 26.07 29.83 ± 21.23 51.90 ± 29.23 
(+) 55 40.36 ± 25.89 46.73 ± 25.10 30.91 ± 25.84 45.27 ± 24.86 36.00 ± 21.31 47.82 ± 29.36 
P value 0.3323 0.5318 0.9225 0.1288 0.1260 0.4610 
Lymphatic 
permeationb
(–) 57 32.98 ± 26.12 44.56 ± 24.35 32.81 ± 26.91 35.26 ± 24.50 30.18 ± 21.92 45.79 ± 27.90 
(+) 53 43.77 ± 28.03 46.42 ± 24.42 31.32 ± 25.27 48.68 ± 25.27 36.60 ± 21.39 53.96 ± 29.70 
P value 0.0389 0.6912 0.7662 0.0056 0.1229 0.1396 
a6 patients can not be confirmed.b9 patients can not be confirmed. outcome (P = 0.0008, Figure 2). The 5-year survival rate in cases
with co-expression of VEGF and MMP-2 was only 32.9%, but it
was 66.7% when the expressions of both VEGF and MMP-2 or
one of them were negative. 
DISCUSSION 
The processes of cancer cell invasion to adjacent tissues and
distant metastasis consist of a complex series of sequential step.
Therefore, we can speculate that several molecular mechanisms
involving specific cancer cells and host characteristics are
probably deeply involved. Angiogenesis seems to be one of the
most important processes of cancer progression, and consists of
proteolysis of the extracellular matrix, proliferation and migration
of endothelial cells, as well as the synthesis of new matrix compo-
nents. In general, it is known that primary lung cancer is one of the
most malignant solid tumours, and that its potential for local inva-
sion and distant metastasis is great. In the present study we
attempted to investigate the immunohistochemical expression
of VEGF, bFGF, PD-ECGF, MMP-2, MMP-9 and c-erbB-2,
which are associated with angiogenesis and proliferation, using
surgically resected specimens of NSCLC and to evaluate the
Angiogenic factors and MMPs in NSCLC 1709
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Figure 1 Kaplan–Meier survival curves for 111 patients with NSCLC. P value was determined with the log-rank test. (A) VEGF (–) vs. VEGF (+). The 5-year
survival rate was 37.5% in VEGF-positive cases, whereas it was 64.4% in VEGF-negative cases (P = 0.0083). (B) bFGF (–) vs. bFGF (+). The 5-year survival
rate was 41.2% in bFGF-positive cases, whereas it was 64.4% in bFGF-negative cases (P = 0.000.0173). (C) MMP- 2 (–) vs. MMP-2 (+). The 5-year 
survival rate was 40.9% in MMP-2-positive cases, whereas it was 69.0% in MMP-2-negative cases (P = 0.0.0149). (D) MMP-9 (–) vs. MMP-9 (+). The
5-year survival rate was 38.4% in MMP-9-positive cases, but it was 68.3% in MMP-9-negative cases (P = 0.0126). (E) PD-ECGF (–) vs. PD-ECGF (+). 
The 5-year survival rate was 46.5% in PD-ECGF-positive cases, and it was 45.9% in PD-ECGF-negative cases (P = 0.8198). (F) c-erbB-2 (–) vs. 
c-erbB-2 (+). The 5-year survival rate was 49.6% in c-erbB-2-positive cases, and it was 37.5% in c-erbB-2-negative cases (P = 0.3004) 
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relationship between the expression levels of each molecule and
clinicopathological factors or prognosis. 
VEGF 
Several previous studies have showed that angiogenesis play an
important role in the cell growth, progression and metastasis of
solid tumours. Ohta et al (1997, 1999) reported a significant corre-
lation between VEGF expression and both tumour size and lymph
node metastasis in primary lung cancer, and they recognized that
VEGF expression was associated not only with distant metastasis
but also with lymphatic metastasis. Some investigators also have
found a significant correlation between VEGF expression and poor
prognosis in NSCLC (Fontanini et al, 1997; Giatromanolaki et al,
1998; Oshika et al 1998; Volm et al, 1999; Ohta et al, 1999). These
data support our present results, that we found the VEGF
expression levels were significantly associated with several kinds
of clinicopathological factors and prognosis. 
bFGF 
There are several reports concerning the relationship between
bFGF expression and the incidence of metastasis. Though statisti-
cally significant differences could not be recognized in pancreatic
carcinoma (Ohta et al, 1995), bFGF seems to be a valuable marker
for lymph node metastasis or distant metastasis in renal cell carci-
noma and gastric carcinoma (Duensing et al, 1995; Ueki et al,
1995; Volm et al, 1999). Several studies concerning NSCLC
showed that bFGF expression was related to progression and prog-
nosis (Takanami et al, 1996; Volm et al, 1997). However,
according to another investigation, bFGF-immunoreactivity of
cancerous cells did not correlate with histological-type tumour
size, nodal status and stage in NSCLC, even though bFGF-
immunoreactivities of stromal cells were associated with lymph
node metastasis and advanced pathological stage in NSCLC
(Guddo et al, 1999). In our own results, no statistically significant
relationship could be observed between bFGF expression levels
and any clinicopathological factor. However, we found there is a
significant association between-bFGF expression and prognosis. 
PD-ECGF 
PD-ECGF is identical to thymidine phosphorylase and possesses
angiogenic activity (Moghaddam and Bicknell, 1992). In
colorectal carcinoma, high expression of PD-ECGF was related to
the extent of tumour invasion, lymphatic and vascular involvement
(Takebayashi et al, 1996). However, another investigator reported
that it was not associated with histological type, the depth of
tumour invasion or lymph node involvement (Maeda et al, 1995).
There is a report concerning NSCLC, in which PD-ECGF did not
prove to be a significantly prognostic factor, but a statistically
significant correlation of PD-ECGF expression with the pT-factor
was recognized (Koukourakis et al, 1997). Our data partially
support those previous results, and show a weak relationship
without statistical significance between PD-ECGF and the pT-
factor (P = 0.059). Furthermore, although we recognized a statisti-
cally significant difference of PD-ECGF expression in relation to
the pN-factor (P = 0.0347), no association between PD-ECGF
expression and prognosis could be observed. 
c-erbB-2 
This molecule is well known as a prognostic factor for breast
cancer and ovarian cancer (Slamon et al, 1987; Tsuda et al, 1989;
Hengstler et al, 1999), and is deeply associated with cell growth
(Giani et al, 1998). According to previous reports concerning
primary lung cancer, the range of overexpression rate is wide
(20–80%) (Kern et al, 1990; Tateishi et al, 1991). Most reports
revealed no statistically significant difference between the overex-
pression and survival probability in adenocarcinoma of the lung
(Giatromanolaki et al, 1996; Pfeiffer et al, 1996). In our study the
positive rate of c-erbB-2 was 78.2%, and no statistically signifi-
cant difference could be recognized concerning clinicopatho-
logical factors and prognosis. 
MMP 
The MMPs, which belong to extracellular endopeptidases, selec-
tively degrade components of the extracellular matrix. Recent
studies showed that the activity of several kinds of MMPs had
increased in the early stages of tumour progression. Especially, the
activities of MMP-2 and MMP-9 were remarkably increased
(Aznavoorian et al, 1993; Wilson and Matrisian, 1996).
Overexpression of MMPs was associated with local invasion to the
adjacent tissues or distant metastasis in NSCLC (Gonzalez-Avila
et al, 1998; Suzuki et al, 1998). MMP-2 has been implicated in
lymphatic and vascular invasion of NSCLC (Brown et al, 1993).
More recently, the MMPs themselves are considered to be angio-
genesis-associated proteins, because either synthetic or endoge-
nous MMP inhibitors inhibit angiogenetic reactivity (Hiraoka et al,
1998). Another study provides direct evidence that MMP-2-
deficient mice exhibit the reduction of angiogenetic response 
and tumour progression in tumour xenografts (Itoh et al, 1998).
Moreover, though capillary endothelial cells cultured on 2-
dimensional type I collagen gels produced low levels of pro-
MMP-2 with little endogenous activation, in 3 dimensional type I
collagen gels there was a marked increase in pro-MMP-2, and
endothelial cells organize lumen formation in multicellular struc-
tures (Haas et al, 1998). Clinically, many investigators reported the
prognostic value of MMP-2 and MMP-9 in NSCLC (Kodate et al,
1997; Cox et al, 2000; Passlick et al, 2000). In our study, MMP-2
positivity was associated with the pN-factor and lymphatic perme-
ation. MMP-9 showed a significant correlation to pT-factor, pN-
factor and p-stage. There were significant relationships between
MMP-2, MMP-9 expression and survival probability. 
Based on multivariate analysis we found VEGF and MMP-2
were independent characteristics affecting the pT-factor and
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Figure 2 Kaplan–Meier survival curves for 111 patients with NSCLC. P value
was determined with the log-rank test. The 5-year survival rate was 32.9% in
cases with co-expression of VEGF and MMP-2, whereas it was 66.7% in
cases with either or both VEGF and MMP-2 negative. Co-expression of VEGF
and MMP-2 was significantly associated with a poor outcome (P = 0.0008) Angiogenic factors and MMPs in NSCLC 1711
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lymphatic permeation, respectively. Garzetti et al (1999) reported
that there was a significant relationship between VEGF and MMP-
2 in immunohistochemical analysis of serous ovarian tumours, and
that the VEGF-positive group showed worse disease-free survival
than the VEGF-negative group. However, there has been no report
concerning the co-expression of VEGF and MMP-2 in NSCLC.
Recently, it was reported that MMPs-2 and -9 are up-regulated in
angiogenic lesions and that MMP-9 could render pancreatic islets in
transgenic mice angiogenic, releasing VEGF (Bergers et al, 2000). It
may be suggested that there are some interactions at the molecular
level between MMPs and VEGF. We found co-overexpression of
VEGF and MMP-2 in 65 out of 111 cases (58.6%) and this was
significantly associated with a poor outcome. Our present investiga-
tion suggested that VEGF and MMP-2 might possess the most valu-
able prognostic impact. Therefore, our data support the hypothesis
that MMPs might generate bio-available VEGF. 
Based on the evidence that angiogenesis plays a crucial role in
tumour progression, angiogenetic factors and proteases are novel
targets for chemotherapeutic strategy, and the use of these
inhibitors requires further evaluation. MMP inhibitors demon-
strated efficacy in preclinical studies using experimental animals
and model system (Johnson et al, 1998; Belotti et al, 1999; Curran
and Murray, 1999; Nelson et al, 2000; Ohta et al, 2001). However,
no clinical efficacy was demonstrated in phrase III drug trials of
MMP inhibitors (Zucker et al, 2000). In spite of considerable
recent progress in identifying the multi-functions of MMPs, MMP
inhibitors and VEGF in cancerous lesions, understanding of the
mechanisms of tumour progression is far from complete. The
present types of clinicopathological investigation may provide a
basis not only for evaluation of tumour malignancy but also for the
preselection of patients to be included in clinical trials to investi-
gate the benefit of new kinds of adjuvant therapy. 
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